Founded in 2009 by Marc Andreessen and Ben Horowitz, Andreessen Horowitz is a venture capital firm based in Menlo Park, California. The firm specializes in incubating and investing in startups across various stages, from seed to late-stage funding. It primarily focuses on sectors such as technology, including software, cloud computing, enterprise software, and consumer Internet. Additionally, it invests in emerging fields like artificial intelligence, fintech, and healthcare, specifically targeting companies at the intersection of technology and life sciences, such as digital therapeutics and computational medicine. Andreessen Horowitz is committed to fostering innovation and supporting companies that contribute to American dynamism, while strategically avoiding investments in areas like clean energy, transportation, and consumer retail.
Operating Partner and Head of Crypto Startup Accelerator
Jay Rughani
Investment Partner
Michael Sandwick
Partner, Consumer
Gil Shafir
Partner
Kristina Shen
General Partner
Jeffrey Silverstein
Partner
Arianna Simpson
General Partner
Sumeet Singh
Partner
Steven Sinofsky
Board Partner
Jack Soslow
Partner
Matt Spence
Partner
Nicole Stanners
Fundraise and IR Partner
Angela Strange
General Partner
Jeffrey Stump
Operating Partner
Jamie Sullivan
Partner
Robert H. Swan
Operating Partner
Satish Talluri
Partner
Kimberly Tan
Investment Partner
Carol Tang
Partner
Adela Tomsejova
Partner, Bio + Health
Dalton Turay
Partner
Gabriel Vasquez
Partner
Melissa Wasser
Partner of Fintech Capital Network
Tyler Wilson
Partner
Daisy Wolf
Investing Partner
Carra Wu
Partner, Crypto Investments
Kevin Wu
Partner
Guy Wuollet
Partner
Shangda Xu
Partner
Zeya Yang
Partner
JJ Yu
Partner, Capital Network
David Ulevitch
General Partner
Frank Chen
Partner
Jonathan Lai
Investment Partner
Matt Bornstein
Partner
Past deals in Medical
IDRx
Series B in 2024
IDRx is a clinical-stage biopharmaceutical company focused on developing precision therapies for oncology, specifically targeting gastrointestinal stromal tumors. The company specializes in designing combination therapies that utilize engineered drug combinations to address key tumor escape mechanisms, aiming to enhance treatment efficacy and prolong patient responses. By creating these targeted therapies, IDRx seeks to revolutionize cancer treatment and support healthcare professionals in delivering more effective medicines to patients.
Q Bio
Venture Round in 2024
Q Bio, founded in 2015 by Jeffrey Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, operates a clinical digital twin platform aimed at assessing patients' medical histories to identify immediate and future health risks. Based in San Carlos, California, the company utilizes whole-body scans to create a digital twin of each patient's physical body, quantifying and digitizing health data. By leveraging simulated human physiology and machine learning, Q Bio's platform can predict potential health risks, enabling healthcare professionals to provide proactive treatment. The interdisciplinary team at Q Bio comprises experts in applied mathematics, computational physics, electrical engineering, genetics, and radiology, supported by prominent venture capital firms.
Thyme Care
Series C in 2024
Thyme Care is a healthcare company focused on providing comprehensive oncology care management services. It partners with health plans to deliver an integrated oncology solution that emphasizes whole-person care for cancer patients. By employing a tech-enabled platform, Thyme Care offers personalized support through physician-guided oncology nurses and resource specialists who educate and guide patients throughout their cancer journey. This model generates actionable insights that help healthcare providers identify at-risk patients earlier, facilitating timely access to quality resources and care. Thyme Care aims to enhance the cancer experience through early and ongoing intervention, ensuring that every cancer patient receives the individualized care they need.
Formation Bio
Series D in 2024
Formation Bio is a biotechnology company dedicated to accelerating drug development and enhancing patient access to new treatments by reimagining clinical trials. The company has developed a platform that scales a network of clinical trial sites integrated within existing medical practices. By utilizing a roaming cohort of certified research coordinators and leveraging advanced software and data analytics, Formation Bio enables researchers to optimize their access to human subjects for various studies, including clinical trials and psychological research. This innovative approach aims to streamline the clinical trial process, ultimately facilitating faster delivery of new therapies to patients.
Pomelo Care
Series B in 2024
Pomelo Care is a leader in evidence-based maternity care, offering comprehensive support for women throughout preconception, pregnancy, birth, postpartum, and their infant’s first year. The company combines virtual, round-the-clock clinical care with in-person doula services to create a unique support model that effectively addresses medical, behavioral, and social factors influencing maternal and infant health. By leveraging data science and machine learning, Pomelo identifies and manages risks associated with pregnancy and postpartum care, aiming to enhance health outcomes while reducing unnecessary costs. The platform provides personalized care plans and resources to meet the specific needs of pregnant individuals and newborns, collaborating with employers as well as commercial and Medicaid health plans to promote accessible and high-quality care.
Santa Ana Bio
Series B in 2024
Santa Ana Bio is a biotechnology company focused on developing precision therapies for autoimmune and inflammatory diseases. By utilizing advanced technologies such as deep cell profiling, single-cell genomics, and multi-omics platforms, the company designs targeted biologics that aim to provide effective and personalized treatment options. Through its innovative approach, Santa Ana Bio seeks to enhance patient outcomes and improve quality of life for those affected by autoimmune conditions.
Elegen
Series B in 2024
Elegen is a biotechnology company founded in 2017, focused on developing microfluidic technology to advance synthetic biology. Led by Dr. Matthew Hill, Elegen aims to revolutionize the field by engineering entire genomes and creating innovative DNA synthesizers. Their technology is designed to enhance the speed and efficiency of DNA sequence testing, thereby facilitating significant progress in biomedical research and healthcare applications. Through these efforts, Elegen seeks to contribute to the rapid development of solutions that address various challenges in the life sciences sector.
Waymark
Venture Round in 2023
Waymark is a company focused on enhancing access to and the quality of healthcare for individuals receiving Medicaid. It offers community-based healthcare services designed to improve health outcomes for Medicaid beneficiaries. The company collaborates with primary care providers and equips community care teams with essential resources, including health plans, insulin education, and training. Through these efforts, Waymark aims to support patients in effectively managing their health and navigating the healthcare system.
Mana.bio
Seed Round in 2023
Mana.bio is an AI-based drug delivery startup that specializes in gene therapy, focusing on both DNA and RNA-based therapeutics as well as vaccines. The company utilizes advanced technology that combines machine learning with nanotechnology to enhance the development of lipid nanoparticle systems, which are crucial for oligonucleotide therapies. By identifying optimal formulations for these delivery systems, Mana.bio aims to improve drug delivery services in the healthcare industry, thereby facilitating more effective therapeutic solutions.
Inceptive
Series A in 2023
Inceptive specializes in the design of RNA molecules through the integration of large-scale deep learning and high-throughput experiments. The company has developed a platform for biological software that facilitates the creation of synthetic molecules capable of performing complex biological functions. By focusing on the rational design of innovative medicines and biotechnologies, Inceptive aims to provide advancements in healthcare and biotechnology that were previously beyond reach.
Genesis Therapeutics
Series B in 2023
Genesis Therapeutics Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing small molecule drug candidates aimed at treating patients with severe and debilitating disorders. Established in 2019, the company harnesses a proprietary artificial intelligence platform that employs advanced deep neural networks and biophysical simulation techniques to enhance drug discovery and molecular design. By combining these innovative technologies with a scalable computing infrastructure, Genesis Therapeutics aims to improve the efficiency and accuracy of molecular research. This approach not only facilitates the generation and analysis of novel drug candidates but also holds the potential to significantly advance clinical outcomes in the medical community.
Amber Bio
Seed Round in 2023
Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations.
Pomelo Care
Series A in 2023
Pomelo Care is a leader in evidence-based maternity care, offering comprehensive support for women throughout preconception, pregnancy, birth, postpartum, and their infant’s first year. The company combines virtual, round-the-clock clinical care with in-person doula services to create a unique support model that effectively addresses medical, behavioral, and social factors influencing maternal and infant health. By leveraging data science and machine learning, Pomelo identifies and manages risks associated with pregnancy and postpartum care, aiming to enhance health outcomes while reducing unnecessary costs. The platform provides personalized care plans and resources to meet the specific needs of pregnant individuals and newborns, collaborating with employers as well as commercial and Medicaid health plans to promote accessible and high-quality care.
Memora Health
Venture Round in 2023
Memora Health Inc., founded in 2016 and based in San Francisco, California, develops an enterprise healthcare productivity platform aimed at automating outpatient communication and enhancing care delivery. The company partners with health systems, health plans, and digital health organizations to streamline clinical workflows, allowing clinicians to focus on their primary responsibilities while proactively engaging patients throughout their care journeys. Memora's platform digitizes high-touch processes, intelligently triaging patient-reported data to the relevant care team members and facilitating proactive, two-way communication between patients and providers. By transforming the way care is delivered, Memora Health seeks to make healthcare more actionable, accessible, and continuous.
Zus Health
Series A in 2023
Zus Health is a healthcare technology company founded in 2020 in Watertown, Massachusetts, by Jonathan Bush. The company develops a healthcare data platform aimed at accelerating digital health initiatives. Its platform uniquely integrates health and non-health data, offering a comprehensive view of patients while facilitating the sharing of clinical and non-clinical information across different applications. This approach empowers healthcare professionals to create customized digital technologies and services that are more affordable and accessible, addressing the common barriers in the healthcare sector. Zus Health is focused on fostering innovation among a new generation of healthcare builders, striving to enhance the overall health experience.
Pearl Health
Venture Round in 2022
Pearl Health is a technology and services company focused on enhancing primary care delivery and improving patient outcomes. Founded in 2020, it partners with thousands of primary care providers across 44 states to facilitate quality healthcare while rewarding providers for maintaining patient health. The company's platform offers a range of tools, including fixed per-member payments, clinical insights through analytics, and assistance with direct contracting programs. These resources enable physicians to concentrate on patient care while also reducing overall healthcare costs and optimizing performance within value-based care models for Traditional Medicare and Medicare Advantage. Pearl Health's team consists of experienced professionals from various fields, including medicine, public health, and technology, all dedicated to addressing significant challenges within the healthcare system.
Firefly Health
Venture Round in 2022
Firefly Health, Inc. is a Massachusetts-based company that develops an artificial intelligence-driven platform to connect patients with healthcare professionals. Founded in 2016, it focuses on providing primary healthcare services that emphasize accessibility and quality. The platform allows users to navigate their health while offering care for common conditions such as back pain, stomach flu, and women's health issues. Firefly Health utilizes a virtual-first approach, enabling patients to access live video appointments with primary care physicians without membership fees. This model facilitates continuous and intelligent care, empowering patients to make informed health choices and allowing clinicians to deliver consistent and proactive support.
Revero
Seed Round in 2022
Revero is an online clinic focused on treating chronic conditions through a root-cause approach. Founded in 2019 and based in San Francisco, California, the company offers personalized treatments for autoimmune and metabolic disorders using nutrition therapy and remote medical care. Revero's platform combines nutritional therapy and clinical expertise with machine learning and digital tools, allowing patients to monitor their health progress and receive tailored feedback. The primary objectives of Revero include helping patients lower blood sugar, improve metabolic health, reduce inflammation, and restore gut health.
Incredible Health
Series B in 2022
Incredible Health, Inc. operates a technology-driven platform that connects healthcare providers with nursing professionals to address staffing challenges. Founded in 2015 and based in San Francisco, the company offers a subscription-based job portal that facilitates the recruitment process for medical candidates. This platform allows users, including fresh graduates, unemployed medical staff, and practicing healthcare professionals, to filter job searches, receive alerts, apply for interviews, and access career advice from recruitment experts. Utilizing AI technology, Incredible Health custom matches healthcare organizations with qualified nurses for hard-to-fill positions, aiming to enhance the hiring experience and improve the lives of healthcare professionals.
IDRx
Series A in 2022
IDRx is a clinical-stage biopharmaceutical company focused on developing precision therapies for oncology, specifically targeting gastrointestinal stromal tumors. The company specializes in designing combination therapies that utilize engineered drug combinations to address key tumor escape mechanisms, aiming to enhance treatment efficacy and prolong patient responses. By creating these targeted therapies, IDRx seeks to revolutionize cancer treatment and support healthcare professionals in delivering more effective medicines to patients.
BigHat Biosciences
Series B in 2022
BigHat is a developer of an AI-guided protein therapeutic platform used to integrate antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.
Cartography Biosciences
Series A in 2022
Cartography Biosciences is a biotechnology company focused on developing cancer therapies through precision medicine. The company has created a platform-based cell therapy that utilizes single-cell analysis to identify innovative CAR-T targets. This approach allows for the design of cancer immunotherapies tailored to the safest and most effective targets. By combining molecular biology and computational methods, Cartography enables clients to advance their studies in the development of these targeted treatments, aiming to improve outcomes for cancer patients.
Tomorrow Health
Series B in 2022
Tomorrow Health is a technology-driven home healthcare company based in New York, New York, that operates an online marketplace for medical supplies and equipment. Founded in 2018, it provides a wide range of products, including wheelchairs, ventilators, prosthetics, and wound care items. The company connects patients, health plans, and home-based care suppliers to improve access to necessary medical equipment while simplifying the ordering and insurance processes. By matching patients with suppliers based on factors such as insurance coverage and service quality, Tomorrow Health aims to streamline logistics and enhance personalized support for families managing care at home. Through its innovative approach, the company seeks to eliminate paperwork and reduce delivery delays, ensuring patients receive the essential supplies they need.
Deepcell
Series B in 2022
Deepcell, Inc. is a biotechnology company based in Mountain View, California, that specializes in providing advanced diagnostic solutions through its innovative microfluidic imaging platform. Founded in 2015, the company focuses on delivering non-invasive tests with diagnostic-level accuracy, enabling researchers and clinicians to gain insights at the single-cell level. Deepcell's technology employs artificial intelligence to analyze and classify cells based on their morphological features, isolating viable cells for various applications in translational research, diagnostic testing, and therapeutics. By utilizing ordinary blood samples, Deepcell enhances the understanding of genetic health without the need for invasive procedures, thereby improving the diagnosis and treatment of diseases.
Memora Health
Venture Round in 2022
Memora Health Inc., founded in 2016 and based in San Francisco, California, develops an enterprise healthcare productivity platform aimed at automating outpatient communication and enhancing care delivery. The company partners with health systems, health plans, and digital health organizations to streamline clinical workflows, allowing clinicians to focus on their primary responsibilities while proactively engaging patients throughout their care journeys. Memora's platform digitizes high-touch processes, intelligently triaging patient-reported data to the relevant care team members and facilitating proactive, two-way communication between patients and providers. By transforming the way care is delivered, Memora Health seeks to make healthcare more actionable, accessible, and continuous.
Topography Health
Series A in 2022
Topography Health is a clinical trials platform designed to facilitate private practice physicians' participation in medical research. The company aids medical practices in understanding their patient demographics and recommends suitable studies that are likely to be effective and well-received. Additionally, Topography assists in patient recruitment and the hiring and management of research staff. By enabling local clinical trials, Topography Health provides patients with various health conditions access to personalized clinical trial opportunities, ultimately advancing medical research and overcoming barriers that physicians face in entering this field.
Nitra
Seed Round in 2022
Nitra is a financial technology company focused on enhancing the healthcare industry through efficient and transparent solutions. The company offers a platform that provides machine learning-powered financial software, including credit cards, loans, accounts, payments, and expense management tailored for medical professionals. Nitra's tools help healthcare providers streamline their spending and manage payments in one centralized location, offering a clear overview of daily expenses. The Nitra Visa Business Card rewards users with benefits for every transaction and provides access to discounts through a network of partners. By simplifying accounting and receipt reconciliation, Nitra aims to support healthcare providers in balancing patient care with efficient practice management, delivering modern technology and dedicated support to the sector.
Waymark
Series A in 2022
Waymark is a company focused on enhancing access to and the quality of healthcare for individuals receiving Medicaid. It offers community-based healthcare services designed to improve health outcomes for Medicaid beneficiaries. The company collaborates with primary care providers and equips community care teams with essential resources, including health plans, insulin education, and training. Through these efforts, Waymark aims to support patients in effectively managing their health and navigating the healthcare system.
Thyme Care
Series A in 2021
Thyme Care is a healthcare company focused on providing comprehensive oncology care management services. It partners with health plans to deliver an integrated oncology solution that emphasizes whole-person care for cancer patients. By employing a tech-enabled platform, Thyme Care offers personalized support through physician-guided oncology nurses and resource specialists who educate and guide patients throughout their cancer journey. This model generates actionable insights that help healthcare providers identify at-risk patients earlier, facilitating timely access to quality resources and care. Thyme Care aims to enhance the cancer experience through early and ongoing intervention, ensuring that every cancer patient receives the individualized care they need.
Pearl Health
Series A in 2021
Pearl Health is a technology and services company focused on enhancing primary care delivery and improving patient outcomes. Founded in 2020, it partners with thousands of primary care providers across 44 states to facilitate quality healthcare while rewarding providers for maintaining patient health. The company's platform offers a range of tools, including fixed per-member payments, clinical insights through analytics, and assistance with direct contracting programs. These resources enable physicians to concentrate on patient care while also reducing overall healthcare costs and optimizing performance within value-based care models for Traditional Medicare and Medicare Advantage. Pearl Health's team consists of experienced professionals from various fields, including medicine, public health, and technology, all dedicated to addressing significant challenges within the healthcare system.
Pomelo Care
Seed Round in 2021
Pomelo Care is a leader in evidence-based maternity care, offering comprehensive support for women throughout preconception, pregnancy, birth, postpartum, and their infant’s first year. The company combines virtual, round-the-clock clinical care with in-person doula services to create a unique support model that effectively addresses medical, behavioral, and social factors influencing maternal and infant health. By leveraging data science and machine learning, Pomelo identifies and manages risks associated with pregnancy and postpartum care, aiming to enhance health outcomes while reducing unnecessary costs. The platform provides personalized care plans and resources to meet the specific needs of pregnant individuals and newborns, collaborating with employers as well as commercial and Medicaid health plans to promote accessible and high-quality care.
Bayesian Health
Venture Round in 2021
Bayesian Health Inc. is a digital health company based in New York, established in 2016. It specializes in an AI-driven platform that enhances patient monitoring by assessing illness severity and detecting changes in acuity. This technology integrates with hospital electronic medical records (EMR), allowing clinical staff and hospital leadership to access real-time data and insights. The platform provides actionable early detection alerts and supports decision-making in complex clinical environments, ultimately optimizing patient care throughout their hospital stay. By leveraging existing investments in EMR systems, Bayesian Health enables healthcare providers to make informed, data-driven decisions that improve safety and efficiency in patient management.
Zus Health
Series A in 2021
Zus Health is a healthcare technology company founded in 2020 in Watertown, Massachusetts, by Jonathan Bush. The company develops a healthcare data platform aimed at accelerating digital health initiatives. Its platform uniquely integrates health and non-health data, offering a comprehensive view of patients while facilitating the sharing of clinical and non-clinical information across different applications. This approach empowers healthcare professionals to create customized digital technologies and services that are more affordable and accessible, addressing the common barriers in the healthcare sector. Zus Health is focused on fostering innovation among a new generation of healthcare builders, striving to enhance the overall health experience.
Nautilus Biotechnology
Post in 2021
Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.
Memora Health
Venture Round in 2021
Memora Health Inc., founded in 2016 and based in San Francisco, California, develops an enterprise healthcare productivity platform aimed at automating outpatient communication and enhancing care delivery. The company partners with health systems, health plans, and digital health organizations to streamline clinical workflows, allowing clinicians to focus on their primary responsibilities while proactively engaging patients throughout their care journeys. Memora's platform digitizes high-touch processes, intelligently triaging patient-reported data to the relevant care team members and facilitating proactive, two-way communication between patients and providers. By transforming the way care is delivered, Memora Health seeks to make healthcare more actionable, accessible, and continuous.
Dyno Therapeutics
Series A in 2021
Dyno Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative adeno-associated virus (AAV) vectors for gene therapy applications. Founded in 2018, the company employs an artificial intelligence-powered platform that integrates next-generation DNA synthesis, high-throughput sequencing, and machine learning. This advanced approach allows Dyno Therapeutics to design and optimize cell-targeting capsids, which are crucial for the effective and safe delivery of gene therapies. By leveraging its technology, the company aims to provide medical researchers with novel AAV vectors that enhance the efficacy of in vivo therapeutic solutions.
Tomorrow Health
Series A in 2021
Tomorrow Health is a technology-driven home healthcare company based in New York, New York, that operates an online marketplace for medical supplies and equipment. Founded in 2018, it provides a wide range of products, including wheelchairs, ventilators, prosthetics, and wound care items. The company connects patients, health plans, and home-based care suppliers to improve access to necessary medical equipment while simplifying the ordering and insurance processes. By matching patients with suppliers based on factors such as insurance coverage and service quality, Tomorrow Health aims to streamline logistics and enhance personalized support for families managing care at home. Through its innovative approach, the company seeks to eliminate paperwork and reduce delivery delays, ensuring patients receive the essential supplies they need.
Firefly Health
Series B in 2021
Firefly Health, Inc. is a Massachusetts-based company that develops an artificial intelligence-driven platform to connect patients with healthcare professionals. Founded in 2016, it focuses on providing primary healthcare services that emphasize accessibility and quality. The platform allows users to navigate their health while offering care for common conditions such as back pain, stomach flu, and women's health issues. Firefly Health utilizes a virtual-first approach, enabling patients to access live video appointments with primary care physicians without membership fees. This model facilitates continuous and intelligent care, empowering patients to make informed health choices and allowing clinicians to deliver consistent and proactive support.
Cedar
Series D in 2021
Cedar is a patient payment and engagement platform for hospitals, health systems, and medical groups that elevate the end-to-end patient experience. The platform leverages advanced data science to customize and simplify the payment experience, resulting in a modern, consumer-friendly way for patients to plan for and pay their bills. It was founded in 2016 and headquartered in New York, United States.
BigHat Biosciences
Series A in 2021
BigHat is a developer of an AI-guided protein therapeutic platform used to integrate antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.
EQRx
Series B in 2021
EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.
Deepcell
Series A in 2020
Deepcell, Inc. is a biotechnology company based in Mountain View, California, that specializes in providing advanced diagnostic solutions through its innovative microfluidic imaging platform. Founded in 2015, the company focuses on delivering non-invasive tests with diagnostic-level accuracy, enabling researchers and clinicians to gain insights at the single-cell level. Deepcell's technology employs artificial intelligence to analyze and classify cells based on their morphological features, isolating viable cells for various applications in translational research, diagnostic testing, and therapeutics. By utilizing ordinary blood samples, Deepcell enhances the understanding of genetic health without the need for invasive procedures, thereby improving the diagnosis and treatment of diseases.
BioAge Labs
Series C in 2020
BioAge Labs, Inc. is a biotechnology company focused on developing therapies to address aging and age-related diseases. The company utilizes a systems biology and artificial intelligence platform to identify key drug targets that influence aging and analyze extensive datasets to uncover the molecular drivers of age-related conditions. BioAge Labs is advancing several drug candidates, including BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor designed to activate genes involved in critical biological processes such as tissue regeneration and vascular remodeling. Additionally, BGE-175, an orally administered inhibitor of the prostaglandin D2 DP1 signaling pathway, aims to mitigate risks associated with immune aging and respiratory infections. Founded in 2015 and based in Richmond, California, BioAge Labs is committed to discovering and developing innovative treatments that harness the biology of human aging.
Cedar
Series C in 2020
Cedar is a patient payment and engagement platform for hospitals, health systems, and medical groups that elevate the end-to-end patient experience. The platform leverages advanced data science to customize and simplify the payment experience, resulting in a modern, consumer-friendly way for patients to plan for and pay their bills. It was founded in 2016 and headquartered in New York, United States.
PatientPing
Series C in 2020
PatientPing, Inc. is a health technology company that has established a national care coordination network designed to connect healthcare providers with real-time notifications whenever patients receive care. The network encompasses a diverse group of healthcare personnel, including physicians, nurses, case managers, and care coordinators across various settings such as hospitals, emergency departments, and skilled nursing facilities. PatientPing offers technology solutions tailored to Accountable Care Organizations (ACOs) and other healthcare providers, facilitating improved collaboration and information sharing. One of its key tools, Spotlights, leverages real-time data to identify utilization and performance trends in patient care. Founded in 2013 and headquartered in Boston, Massachusetts, PatientPing operates as a subsidiary of SVB Leerink Holdings LLC and maintains a strategic partnership with MedAllies, Inc. By fostering connections among care teams, PatientPing aims to enhance the quality and efficiency of healthcare delivery, ultimately leading to better patient outcomes.
Nautilus Biotechnology
Series B in 2020
Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.
Topography Health
Venture Round in 2020
Topography Health is a clinical trials platform designed to facilitate private practice physicians' participation in medical research. The company aids medical practices in understanding their patient demographics and recommends suitable studies that are likely to be effective and well-received. Additionally, Topography assists in patient recruitment and the hiring and management of research staff. By enabling local clinical trials, Topography Health provides patients with various health conditions access to personalized clinical trial opportunities, ultimately advancing medical research and overcoming barriers that physicians face in entering this field.
Tomorrow Health
Seed Round in 2020
Tomorrow Health is a technology-driven home healthcare company based in New York, New York, that operates an online marketplace for medical supplies and equipment. Founded in 2018, it provides a wide range of products, including wheelchairs, ventilators, prosthetics, and wound care items. The company connects patients, health plans, and home-based care suppliers to improve access to necessary medical equipment while simplifying the ordering and insurance processes. By matching patients with suppliers based on factors such as insurance coverage and service quality, Tomorrow Health aims to streamline logistics and enhance personalized support for families managing care at home. Through its innovative approach, the company seeks to eliminate paperwork and reduce delivery delays, ensuring patients receive the essential supplies they need.
Devoted
Series C in 2020
Devoted Health is a healthcare company focused on enhancing the health and well-being of older Americans by treating each individual with care and compassion. The company offers an integrated healthcare solution that includes Medicare Advantage plans, access to local providers, and the option for virtual and in-home care through Devoted Medical. Their approach includes personalized medical plans and dedicated guides who work closely with physicians to streamline care and minimize unnecessary procedures. By leveraging advanced technology and a robust network of healthcare professionals, Devoted Health aims to provide high-quality, tailored healthcare services to its members.
Q Bio
Series B in 2020
Q Bio, founded in 2015 by Jeffrey Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, operates a clinical digital twin platform aimed at assessing patients' medical histories to identify immediate and future health risks. Based in San Carlos, California, the company utilizes whole-body scans to create a digital twin of each patient's physical body, quantifying and digitizing health data. By leveraging simulated human physiology and machine learning, Q Bio's platform can predict potential health risks, enabling healthcare professionals to provide proactive treatment. The interdisciplinary team at Q Bio comprises experts in applied mathematics, computational physics, electrical engineering, genetics, and radiology, supported by prominent venture capital firms.
EQRx
Series A in 2020
EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.
Genesis Therapeutics
Seed Round in 2019
Genesis Therapeutics Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing small molecule drug candidates aimed at treating patients with severe and debilitating disorders. Established in 2019, the company harnesses a proprietary artificial intelligence platform that employs advanced deep neural networks and biophysical simulation techniques to enhance drug discovery and molecular design. By combining these innovative technologies with a scalable computing infrastructure, Genesis Therapeutics aims to improve the efficiency and accuracy of molecular research. This approach not only facilitates the generation and analysis of novel drug candidates but also holds the potential to significantly advance clinical outcomes in the medical community.
Incredible Health
Series A in 2019
Incredible Health, Inc. operates a technology-driven platform that connects healthcare providers with nursing professionals to address staffing challenges. Founded in 2015 and based in San Francisco, the company offers a subscription-based job portal that facilitates the recruitment process for medical candidates. This platform allows users, including fresh graduates, unemployed medical staff, and practicing healthcare professionals, to filter job searches, receive alerts, apply for interviews, and access career advice from recruitment experts. Utilizing AI technology, Incredible Health custom matches healthcare organizations with qualified nurses for hard-to-fill positions, aiming to enhance the hiring experience and improve the lives of healthcare professionals.
Omada
Series D in 2019
Omada Health, Inc. is a digital healthcare company that creates and implements online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health focuses on helping employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the unique needs of participants, incorporating professional health coaching, connected health devices, and real-time data to foster sustainable lifestyle changes. Omada Health is recognized as the largest provider of the National Diabetes Prevention Program, delivering clinically effective solutions that empower individuals to take charge of their health and achieve their wellness goals.
BioAge Labs
Series B in 2019
BioAge Labs, Inc. is a biotechnology company focused on developing therapies to address aging and age-related diseases. The company utilizes a systems biology and artificial intelligence platform to identify key drug targets that influence aging and analyze extensive datasets to uncover the molecular drivers of age-related conditions. BioAge Labs is advancing several drug candidates, including BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor designed to activate genes involved in critical biological processes such as tissue regeneration and vascular remodeling. Additionally, BGE-175, an orally administered inhibitor of the prostaglandin D2 DP1 signaling pathway, aims to mitigate risks associated with immune aging and respiratory infections. Founded in 2015 and based in Richmond, California, BioAge Labs is committed to discovering and developing innovative treatments that harness the biology of human aging.
Q Bio
Series A in 2018
Q Bio, founded in 2015 by Jeffrey Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, operates a clinical digital twin platform aimed at assessing patients' medical histories to identify immediate and future health risks. Based in San Carlos, California, the company utilizes whole-body scans to create a digital twin of each patient's physical body, quantifying and digitizing health data. By leveraging simulated human physiology and machine learning, Q Bio's platform can predict potential health risks, enabling healthcare professionals to provide proactive treatment. The interdisciplinary team at Q Bio comprises experts in applied mathematics, computational physics, electrical engineering, genetics, and radiology, supported by prominent venture capital firms.
Scribe Therapeutics
Series A in 2018
Scribe Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutics based on CRISPR technology to address genetic disorders. Founded in 2017 and headquartered in Berkeley, California, the company utilizes its proprietary X-Editing (XE) platform, which features highly engineered CRISPR enzymes designed to improve the efficacy, specificity, and deliverability of genome editing. Scribe Therapeutics aims to overcome existing limitations in genetic medicine by creating custom-engineered enzymes and advanced delivery systems. Their approach seeks to establish CRISPR-based therapies as a new standard in clinical care, potentially transforming the treatment landscape for various conditions, including immuno-oncology, degenerative disorders, and enzyme replacement therapy. By prioritizing therapeutic precision and allele-specific targeting, Scribe Therapeutics is committed to expanding access to groundbreaking treatments that can significantly impact patient lives.
Deepcell
Seed Round in 2017
Deepcell, Inc. is a biotechnology company based in Mountain View, California, that specializes in providing advanced diagnostic solutions through its innovative microfluidic imaging platform. Founded in 2015, the company focuses on delivering non-invasive tests with diagnostic-level accuracy, enabling researchers and clinicians to gain insights at the single-cell level. Deepcell's technology employs artificial intelligence to analyze and classify cells based on their morphological features, isolating viable cells for various applications in translational research, diagnostic testing, and therapeutics. By utilizing ordinary blood samples, Deepcell enhances the understanding of genetic health without the need for invasive procedures, thereby improving the diagnosis and treatment of diseases.
BioAge Labs
Series A in 2017
BioAge Labs, Inc. is a biotechnology company focused on developing therapies to address aging and age-related diseases. The company utilizes a systems biology and artificial intelligence platform to identify key drug targets that influence aging and analyze extensive datasets to uncover the molecular drivers of age-related conditions. BioAge Labs is advancing several drug candidates, including BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor designed to activate genes involved in critical biological processes such as tissue regeneration and vascular remodeling. Additionally, BGE-175, an orally administered inhibitor of the prostaglandin D2 DP1 signaling pathway, aims to mitigate risks associated with immune aging and respiratory infections. Founded in 2015 and based in Richmond, California, BioAge Labs is committed to discovering and developing innovative treatments that harness the biology of human aging.
Freenome
Series A in 2017
Freenome, Inc. is a biotechnology company based in South San Francisco, California, founded in 2014. It specializes in developing artificial intelligence-driven genomic solutions for the early detection of cancer. The company focuses on creating simple, non-invasive blood tests that can identify early-stage cancer and assist in treatment selection, thus enabling proactive disease management. Freenome’s multi-omics platform employs proprietary algorithms to enhance disease screening processes, aiming to facilitate timely interventions and improve treatment effectiveness. In addition to its diagnostic products, Freenome also offers clinical research services to support its mission of transforming cancer management through systematic early detection.
PatientPing
Series B in 2016
PatientPing, Inc. is a health technology company that has established a national care coordination network designed to connect healthcare providers with real-time notifications whenever patients receive care. The network encompasses a diverse group of healthcare personnel, including physicians, nurses, case managers, and care coordinators across various settings such as hospitals, emergency departments, and skilled nursing facilities. PatientPing offers technology solutions tailored to Accountable Care Organizations (ACOs) and other healthcare providers, facilitating improved collaboration and information sharing. One of its key tools, Spotlights, leverages real-time data to identify utilization and performance trends in patient care. Founded in 2013 and headquartered in Boston, Massachusetts, PatientPing operates as a subsidiary of SVB Leerink Holdings LLC and maintains a strategic partnership with MedAllies, Inc. By fostering connections among care teams, PatientPing aims to enhance the quality and efficiency of healthcare delivery, ultimately leading to better patient outcomes.
Cardiogram
Seed Round in 2016
Cardiogram, Inc., established in 2015 and based in San Francisco, California, specializes in developing wearable devices and applications to monitor and analyze heart health. The company's technology enables users to track heart rate measurements, providing insights into how their heart responds during workouts and how various factors such as stress, diet, and exercise affect their resting heart rate. The application supports cardio-tracking for devices like the Apple Watch and Android Wear, allowing users to detect heartbeats, monitor sleep, and maintain fitness. By enabling users to visualize and share their heart rate data, Cardiogram aims to help prevent serious heart-related issues such as strokes.
Q Bio
Seed Round in 2016
Q Bio, founded in 2015 by Jeffrey Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, operates a clinical digital twin platform aimed at assessing patients' medical histories to identify immediate and future health risks. Based in San Carlos, California, the company utilizes whole-body scans to create a digital twin of each patient's physical body, quantifying and digitizing health data. By leveraging simulated human physiology and machine learning, Q Bio's platform can predict potential health risks, enabling healthcare professionals to provide proactive treatment. The interdisciplinary team at Q Bio comprises experts in applied mathematics, computational physics, electrical engineering, genetics, and radiology, supported by prominent venture capital firms.
Omada
Series C in 2015
Omada Health, Inc. is a digital healthcare company that creates and implements online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health focuses on helping employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the unique needs of participants, incorporating professional health coaching, connected health devices, and real-time data to foster sustainable lifestyle changes. Omada Health is recognized as the largest provider of the National Diabetes Prevention Program, delivering clinically effective solutions that empower individuals to take charge of their health and achieve their wellness goals.
Human API
Series A in 2015
Human API is a digital health data network that allows consumers to easily access and share their health information from various sources, including hospitals, electronic medical records, pharmacies, labs, and wearable devices. Founded in 2013 and based in San Mateo, California, the company connects to data from 90% of US hospitals and over 300 wellness applications. The platform employs a machine learning-powered data pipeline to standardize health data, making it more accessible and actionable for medical researchers and scientists. Importantly, it empowers consumers to maintain control over their personal health data, determining which companies can access their information. This streamlined approach addresses the challenges of fragmented health data sources, facilitating efficient data sharing and utilization in the healthcare ecosystem.
uBiome
Series A in 2014
uBiome, Inc. was a microbial genomics company based in San Francisco, California, specializing in sequencing-based clinical microbiome tests. Founded in 2012, it offered a range of products including SmartGut, a test for identifying harmful and beneficial microorganisms linked to specific infections; SmartJane, a women’s health screening for conditions like HPV and STIs; Explorer kits for researchers and citizen scientists; and SmartFlu, a clinical test for respiratory infections. The company's goal was to enhance understanding of the human microbiome and its implications for health. However, uBiome faced financial difficulties and filed for Chapter 11 bankruptcy in September 2019, which was later converted to Chapter 7 on October 11, 2019, marking the end of its operations.
Omada
Series B in 2014
Omada Health, Inc. is a digital healthcare company that creates and implements online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health focuses on helping employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the unique needs of participants, incorporating professional health coaching, connected health devices, and real-time data to foster sustainable lifestyle changes. Omada Health is recognized as the largest provider of the National Diabetes Prevention Program, delivering clinically effective solutions that empower individuals to take charge of their health and achieve their wellness goals.
Human API
Seed Round in 2013
Human API is a digital health data network that allows consumers to easily access and share their health information from various sources, including hospitals, electronic medical records, pharmacies, labs, and wearable devices. Founded in 2013 and based in San Mateo, California, the company connects to data from 90% of US hospitals and over 300 wellness applications. The platform employs a machine learning-powered data pipeline to standardize health data, making it more accessible and actionable for medical researchers and scientists. Importantly, it empowers consumers to maintain control over their personal health data, determining which companies can access their information. This streamlined approach addresses the challenges of fragmented health data sources, facilitating efficient data sharing and utilization in the healthcare ecosystem.
CrowdMed
Seed Round in 2013
CrowdMed, Inc. operates an online platform that utilizes prediction market technology to assist patients in diagnosing complex medical conditions. Founded in 2012 and based in San Francisco, CrowdMed connects patients with a network of medical detectives, including licensed physicians, medical students, and other healthcare professionals, to collaboratively solve challenging medical cases. By leveraging the collective intelligence of thousands of contributors, the platform provides patients with insightful diagnostic suggestions for their unresolved symptoms. This approach not only aims to expedite the diagnostic process for individuals who have struggled with chronic health issues but also seeks to reduce healthcare costs while maintaining quality care. CrowdMed's innovative model positions it as a trusted resource for patients seeking clarity and solutions in their healthcare journeys.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.